Calcification-resistant materials and methods of making same through use of multivalent cations

• US 5,679,112 A
• Filed: 11/28/1994
• Issued: 10/21/1997
• Est. Priority Date: 04/01/1988
• Status: Expired due to Term

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Levy, Robert J., Sintov, Amnon
• Primary Examiner(s): Caldarola, Glenn A.
• Assistant Examiner(s): BULLOCK, IN SUK C
• Application Number:
  US08/345,658
• Time in Patent Office: 1,058 Days
• Field of Search: 8/94.11, 8/94.19, 8/94.18, 8/94.28, 623/1-3, 623/11, 623/12, 623/66
• US Class Current: 8/94.11
• CPC Class Codes: A61L 2300/102 Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
• CPC Class Codes: A61L 2300/21 Acids
• CPC Class Codes: A61L 2300/216 with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
• CPC Class Codes: A61L 2300/40 characterised by a specific therapeutic activity or mode of action
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 2430/40 Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: Y10S 128/08 Collagen
• CPC Class Codes: Y10S 623/921 Blood vessel

Abstract

Bioprosthetic materials, either natural or synthetic, are treated with trivalent iron cations, or salts, to prevent in vivo calcification. Such bioprosthetic materials include porcine aortic valve leaflets, bovine pericardium, aortic homografts, biocompatible elastomers, and the like which are intended for invasive, or in-dwelling use in a human or animal body. Simple incubation of the natural bioprosthetic materials in an iron ion-containing solution, such as aqueous FeCl₃, particularly with the addition of an anticalcification agent, such as a diphosphonate, prior to implantation has been found to inhibit calcification of the biomaterial over a prolonged period, and to do so without adverse side effects. Incorporation of an iron-containing compound, with or without an additional anticalcification agent, into the formulation for polymers, such as polyurethane, has also been found to inhibit calcification with no adverse side effects.

Claims

1. An implant formed of a biocompatible biomaterial which is a tissue which occurs naturally in a donor living being and is insoluble in the interior of the body of a host living being, said biomaterial having incorporated therein an effective amount of trivalent iron cations and at least one anticalcification agent selected from the group consisting of citrates and diphosphonates to render said biomaterial resistant to in vivo pathologic calcification.

2. The implant of claim 1 wherein said biomaterial is selected from the group consisting of bovine pericardium, porcine heart valve leaflets, saphenous bypass grafts, and aortic homografts.

3. An implant formed of a biocompatible biomaterial which is a biocompatible synthetic polymer and is insoluble in the interior of the body of a host living being, said biomaterial having incorporated therein an effective amount of trivalent iron cations to render said biomaterial resistant to in vivo pathologic calcification.

4. The implant of claim 3 wherein said biocompatible synthetic polymer is an organic synthetic material selected from the group consisting of polydimethylsiloxane, polyurethane, ethylene vinyl acetate, polymethyl methacrylate, polyamide, polycarbonate, polyester, polyethylene, polypropylene, polystyrene, polyvinyl chloride, polytetrafluoroethylene, polysulfone, and cellulose acetate.

5. The implant of claim 4 wherein said organic synthetic material is a polyurethane.

19. The implant of claim 3 having further incorporated therein at least one anticalcification agent.

20. The implant of claim 19 wherein the at least one anticalcification agent is selected from the group consisting of citrates and diphosphonates.

6. A material suitable for implantation in the interior of the body of a living being, the material being a tissue which occurs naturally in a donor living being having incorporated therein an effective amount of trivalent iron cations and at least one anticalcification agent selected from the group consisting of citrates and diphosphonates to render the tissue resistant to pathologic calcification in an in vivo environment.

7. The material of claim 6 wherein said tissue is selected from the group consisting of bovine pericardium, porcine heart valve leaflets, saphenous bypass grafts, and aortic homografts.

8. A material suitable for implantation the interior of the body of a living being, the material being a biocompatible biomaterial which is a biocompatible synthetic polymer having incorporated therein an effective amount of trivalent iron cations to render the biomaterial resistant to pathologic calcification in an in vivo environment.

9. The material of claim 8 wherein the biocompatible synthetic polymer is selected from the group consisting of polydimethylsiloxane, polyurethane, ethylene vinyl acetate, polymethyl methacrylate, polyamide, polycarbonate, polyester, polyethylene, polypropylene, polystyrene, polyvinyl chloride, polytetrafluoroethylene, polysulfone, and cellulose acetate.

21. The material of claim 8 having further incorporated therein at least one anticalcification agent.

22. The material of claim 21 wherein the at least one anticalcification agent is selected from the group consisting of citrates and diphosphonates.

10. A material for implanting in the interior of a human or animal living body, the material being prepared by the process of:

(a) dissolving a biocompatible synthetic polymeric material in an organic solvent;

(b) adding a soluble salt of trivalent iron cations to the dissolved biocompatible synthetic polymeric material to form a mixture; and

(c) forming said mixture into a desired configuration.

11. The material for implanting in the interior of a human or animal living body prepared by the process of claim 10 wherein said step of forming said mixture into said desired configuration comprises the step of casting said mixture into a film.

12. The material for implanting in the interior of a human or animal living body prepared by the process of claim 11 further comprising the step of drying the cast film in a vacuum oven at 50°

to 55°

C.

13. The material for implanting in the interior of a human or animal living body prepared by the process of claim 10 wherein said step of forming said mixture into said desired configuration comprises the step of molding said mixture.

14. The material for implanting in the interior of a human or animal living body prepared by the process of claim 10 wherein said biocompatible synthetic polymeric material is selected from the group consisting of polydimethylsiloxane, polyurethane, ethylene vinyl acetate, polymethyl methacrylate, polyamide, polycarbonate, polyester, polyethylene, polypropylene, polystyrene, polyvinyl chloride, polytetrafluoroethylene, polysulfone, and cellulose acetate.

15. The material for implanting in the interior of a human or animal living body prepared by the process of claim 14 wherein said biocompatible synthetic polymeric material is selected from the group consisting of polyurethanes and polydimethylsiloxanes and copolymers thereof, and said organic solvent is selected from the group consisting of dimethyl sulfoxide, dimethylacetamide, and tetrahydrofuran.

16. The material for implanting in the interior of a human or animal living body prepared by the process of claim 15 wherein said synthetic polymeric material is polyurethane and said organic solvent is dimethyl sulfoxide.

17. The material for implanting in the interior of a human or animal living body prepared by the process of claim 10 wherein said soluble salt of trivalent iron is selected from the group consisting of ferric acetate, ferric chloride, ferric nitrate, ferric bromide, ferric sodium edentate, ferric sulfate, and ferric formate.

18. The material for implanting in the interior of a human or animal living body prepared by the process of claim 10 wherein step (b) further includes adding a soluble anticalcification agent selected from the group consisting of citrates and diphosphonates.

23. A material for implanting in the interior of a human or animal living body prepared by the process of:

incubating a glutaraldehyde pre-treated bioprosthetic tissue in an aqueous solution of soluble salt of trivalent iron and an anticalcification agent selected from the group consisting of citrates and diphosphonates, the soluble salt of trivalent iron and the anticalcification agent selected from the group consisting of citrates and diphosphonates having concentrations in the range of from about 0.1M to 0.00001M for a period of time ranging from approximately between 1 hour to 24 hours at a temperature of approximately between 4°

C. to 25°

C.

24. The material of claim 23 wherein the soluble salt of trivalent iron is selected from the group consisting of ferric acetate, ferric chloride, ferric nitrate, ferric bromide, ferric sodium edentate, ferric sulfate, and ferric formate.